S. Whittle

Is high‐risk neuroblastoma induction chemotherapy possible without G‐CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors

P. Zage, C. Minard, H. Russell, 2020, Pediatric blood & cancer.

Overview and recent advances in the treatment of neuroblastoma

P. Zage, S. Whittle, Valeria R Smith, 2017, Expert review of anticancer therapy.

Factors Impacting Time to Engraftment in Patients With High-risk Neuroblastoma Following Autologous Stem Cell Transplant

R. Krance, S. Whittle, J. Foster, 2020, Journal of pediatric hematology/oncology.

Incidence and risk factors of bacterial and fungal infection during induction chemotherapy for high-risk neuroblastoma

H. Russell, S. Whittle, Kaitlin C Williamson, 2017, Pediatric hematology and oncology.

Congenital spindle cell rhabdomyosarcoma

Angshumoy Roy, M. Hicks, S. Vasudevan, 2019, Pediatric blood & cancer.

Therapy-related Acute Leukemia With Mixed Phenotype and Novel t(1: 6)(q25;p23) After Treatment for High-risk Neuroblastoma

O. Hampton, D. Lopez-Terrada, S. Whittle, 2017, Journal of pediatric hematology/oncology.

The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma

P. Zage, S. Whittle, Valeria R Smith, 2016, Investigational New Drugs.

An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma

C. Antonescu, B. Crompton, E. Álava, 2022, npj Precision Oncology.